← Leaderboards
Duane A. Mitchell
Duke University
$34,257,734
Attributed
$43,373,580
Total exposure
10
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $8.8M · FY2009–25$10M$7.5M$5M$2.5M$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$43,373,580 · 10
By mechanism
UL1$23,411,818 · 1
R01$14,307,864 · 7
UM1$5,377,354 · 1
R42$276,544 · 1
Top collaborators
- John H Sampson6 shared
- Jeffrey K Harrison5 shared
- Roger Packer5 shared
- Kelly K. Gurka1 shared
- Matthew James Gurka1 shared
- Hui Hu1 shared
- Sylvie Naar-King1 shared
- Carlos M Rinaldi-Ramos1 shared
Most similar at Duke University
Same institution · by research overlap
- John H Sampson$43,413,436
- David Reardon$8,732,934
- Yiping Yang$13,692,641
- Johannes W.g. Vieweg$4,142,091
- David M. Ashley$7,073,119
Others in their field
Top investigators on “Tumor”
- David Heimbrook · Leidos Biomedical Research, Inc.$636,492,067
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Gregory H Reaman · National Childhood Cancer Foundation$208,276,509
- Richard K. Wilson · Washington University$203,917,615
- Norman Wolmark · Nsabp Foundation, Inc.$177,323,696
- Ronald T Mitsuyasu · University Of California Los Angeles$138,361,819
Research focus
TumorMalignant NeoplasmsResponseClinical TrialsIn VivoDiagnosisMalignant GliomaMalignant Neoplasm Of BrainBrainDendritic CellsIn VitroImmunotherapyGlioblastomaCellsImmunologicsT-LymphocyteCancer TherapyPathway InteractionsNewly DiagnosedMediatingPhysiologic PulseSiteCoupledMalignant - Descriptor
Grant awards (40)
INSiGHTS - Innovative Next Steps in Gaining Health Improvements Through Translational Science$5,377,354
UM1 · FY2025 · TR · contact PI
Nanotechnology enabled quantitative imaging of dendritic cell anti-cancer vaccines$2,628,974
R01 · FY2025 · CA
Addressing tumor heterogeneity in pediatric gliomas with precision adoptive T cell therapy$474,656
R01 · FY2025 · CA · contact PI
Overcoming Immune Checkpoint Blockade Resistance in Glioblastoma with a Novel Stem Cell Biotherapeutic$276,544
R42 · FY2025 · CA
Together: Transforming and Translating Discovery to Improve Health$508,965
UL1 · FY2024 · TR · contact PI
Addressing tumor heterogeneity in pediatric gliomas with precision adoptive T cell therapy$474,656
R01 · FY2024 · CA · contact PI
Together: Transforming and Translating Discovery to Improve Health$4,614,752
UL1 · FY2023 · TR · contact PI
Together: Transforming and Translating Discovery to Improve Health$3,403,322
UL1 · FY2022 · TR · contact PI
Targeting CCR2-expressing myeloid cells to overcome immune checkpoint inhibitor resistance in glioma$378,934
R01 · FY2022 · NS
Together: Transforming and Translating Discovery to Improve Health$195,137
UL1 · FY2022 · TR · contact PI
Together: Transforming and Translating Discovery to Improve Health$4,651,356
UL1 · FY2021 · TR · contact PI
Targeting CCR2-expressing myeloid cells to overcome immune checkpoint inhibitor resistance in glioma$378,934
R01 · FY2021 · NS
Together: Transforming and Translating Discovery to Improve Health$195,137
UL1 · FY2021 · TR · contact PI
CTSA Program: Admin Supplements for Quality Assurance/Quality Control Position$42,561
UL1 · FY2021 · TR · contact PI
Together: Transforming and Translating Discovery to Improve Health$4,768,819
UL1 · FY2020 · TR · contact PI
Targeting CCR2-expressing myeloid cells to overcome immune checkpoint inhibitor resistance in glioma$378,934
R01 · FY2020 · NS
Efficacy of Dendritic Cell Vaccines Targeting CMV in Glioblastoma (phase 2 DC vaccine)$269,745
R01 · FY2020 · CA · contact PI
Together: Transforming and Translating Discovery to Improve Health$228,576
UL1 · FY2020 · TR · contact PI
Together: Transforming and Translating Discovery to Improve Health$4,803,193
UL1 · FY2019 · TR · contact PI
Efficacy of Dendritic Cell Vaccines Targeting CMV in Glioblastoma (phase 2 DC vaccine)$677,349
R01 · FY2019 · CA · contact PI
Enhancing Adoptive Immunotherapy Targeting Pediatric High-Grade Gliomas$614,852
R01 · FY2019 · CA · contact PI
Targeting CCR2-expressing myeloid cells to overcome immune checkpoint inhibitor resistance in glioma$378,934
R01 · FY2019 · NS
Efficacy of Dendritic Cell Vaccines Targeting CMV in Glioblastoma (phase 2 DC vaccine)$703,160
R01 · FY2018 · CA · contact PI
Enhancing Adoptive Immunotherapy Targeting Pediatric High-Grade Gliomas$633,869
R01 · FY2018 · CA · contact PI
Targeting CCR2-expressing myeloid cells to overcome immune checkpoint inhibitor resistance in glioma$375,159
R01 · FY2018 · NS
Enhancing Adoptive Immunotherapy Targeting Pediatric High-Grade Gliomas$633,869
R01 · FY2017 · CA · contact PI
Efficacy of Dendritic Cell Vaccines Targeting CMV in Glioblastoma (phase 2 DC vaccine)$185,105
R01 · FY2017 · CA · contact PI
Efficacy of Dendritic Cell Vaccines Targeting CMV in Glioblastoma (phase 2 DC vaccine)$616,384
R01 · FY2016 · CA · contact PI
Enhancing Adoptive Immunotherapy Targeting Pediatric High-Grade Gliomas$492,969
R01 · FY2016 · CA · contact PI
Efficacy of Dendritic Cell Vaccines Targeting CMV in Glioblastoma (phase 2 DC vaccine)$634,471
R01 · FY2015 · CA · contact PI
Enhancing Adoptive Immunotherapy Targeting Pediatric High-Grade Gliomas$460,837
R01 · FY2015 · CA · contact PI
Reversal of CMV-specific Immune Deficits in Patients with Glioblastoma$308,239
R01 · FY2013 · NS · contact PI
Reversal of CMV-specific immune deficits in patients with glioblastoma$332,401
R01 · FY2012 · NS · contact PI
Adoptive Immunotherapy for GBM During Hematopoietic Recovery from Temozolomide$312,186
R01 · FY2012 · CA · contact PI
Reversal of CMV-specific immune deficits in patients with glioblastoma$332,401
R01 · FY2011 · NS · contact PI
Adoptive Immunotherapy for GBM During Hematopoietic Recovery from Temozolomide$312,186
R01 · FY2011 · CA · contact PI
Reversal of CMV-specific immune deficits in patients with glioblastoma$335,793
R01 · FY2010 · NS · contact PI
Adoptive Immunotherapy for GBM During Hematopoietic Recovery from Temozolomide$321,841
R01 · FY2010 · CA · contact PI
Reversal of CMV-specific immune deficits in patients with glioblastoma$339,185
R01 · FY2009 · NS · contact PI
Adoptive Immunotherapy for GBM During Hematopoietic Recovery from Temozolomide$321,841
R01 · FY2009 · CA · contact PI